Capecitabine and Temozolomide in NETs G1-2: The Experience of Various Hospitals in Spain

#1389

Introduction: Treatment of neuroendocrine tumors (NETs) with capecitabine-temozolomide (CAPTEM) is an option yet to be confirmed in phase III trials.

Aim(s): The experience of 12 centers in Spain with this scheme is presented.

Materials and methods: We retrospectively reviewed patients with NETs G1-2 of any origin treated with capecitabine (750-1000 mg/m2 twice daily days 1-14) and temozolomide (150-200 mg/m2 days 10-14) every 28 days, from June 2009 to August 2015.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Crespo G, Jimenez-Fonseca P, Custodio A, Lopez C, Carmona-Bayonas A,

Keywords: capecitabine, temozolomide,